Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

# Filgotinib

## Catalog No: tcsc2284

### Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg

**Size:** 100mg

### Specifications

**CAS No:**
1206161-97-8

**Formula:**
$C_{21}H_{23}N_5O_3S$

**Pathway:**
Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling

**Target:**
JAK;JAK;JAK

**Purity / Grade:**
>98%

**Solubility:**
DMSO : 6.8 mg/mL (15.98 mM; Need ultrasonic and warming); H2O :

**Alternative Names:**
GLPG0634

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

**Observed Molecular Weight:**
425.5

## Product Description

Filgotinib (GLPG0634) is a selective **JAK1** inhibitor with **$IC_{50}$** of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

IC50 & Target: IC50: 10 nM (JAK1), 28 nM (JAK2), 810 nM (JAK3), 116 nM (Tyk2)

***In Vitro:*** Filgotinib (GLPG0634) dose-dependently inhibits the differentiation of Th2 cells mediated by IL-4, a cytokine that signals through JAK1 and JAK3. Filgotinib also inhibits Th1 differentiation with similar potencies of 1 μM or lower[1]. Filgotinib (GLPG0634) does not inhibit JAK2 homodimer-mediated signaling induced by EPO or PRL ($IC_{50}$ > 10 μM)[2].

***In Vivo:*** Filgotinib (GLPG0634; 3, 10, 30 mg/kg, p.o.) dose-dependently prevents disease progression in the therapeutic rat CIA model. Filgotinib (50 mg/kg, o.p.) protects bone and cartilage from degradation, effectively reduces infiltration of T cells ($CD3^+$ cells) and macrophages ($F4/80^+$ cells) in the paw, and decreases the serum levels of all cytokines and chemokines measured, including IL-6, IP-10, XCL1, and MCP-1[1]. Filgotinib (GLPG0634; 0.1 and 0.3 mg/kg) shows efficacy in the rat CIA model[2].